Evidence map›Paper›PMID 34577930›Full record

ArticlePolymers2021

Safety and Efficacy of Kartigen

Yen-Liang Liu, Chun-Che Yen, Tzu-Shang Thomas Liu, Chih-Hung Chang, Tiffany Ting-Fang Shih, Jyh-Horng Wang, Ming-Chia Yang, Feng-Huei Lin, Hwa-Chang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Polymers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yen-Liang LiuMaster Program for Biomedical Engineering, College of Biomedical Engineering, China Medical University, Taichung 406040, Taiwan.ORCID 0000-0002-1635-4335
Chun-Che YenKartigen Biomedical Inc., Taipei 100047, Taiwan.
Tzu-Shang Thomas LiuSouthern California Bone and Joint Clinic, Apple Valley, CA 92307, USA.
Chih-Hung ChangDepartment of Orthopaedic Surgery, Far Eastern Memorial Hospital, New Taipei 220216, Taiwan.
Tiffany Ting-Fang ShihDepartment of Medical Imaging and Radiology, National Taiwan University Hospital, Taipei 100225, Taiwan.
Jyh-Horng WangDepartment of Orthopaedic Surgery, National Taiwan University Hospital, Taipei 100225, Taiwan.
Ming-Chia YangBiomedical Technology and Device Research Laboratories, Industrial Technology Research Institute, Hsinchu 310401, Taiwan.
Feng-Huei LinDepartment of Biomedical Engineering, College of Engineering, National Taiwan University, Taipei 106319, Taiwan.ORCID 0000-0002-2994-6671
Hwa-Chang LiuDepartment of Orthopaedic Surgery, National Taiwan University Hospital, Taipei 100225, Taiwan.

Funding

Kartigen Biomedical Inc. NA
6 · The paper itself

Abstract

Here, we aimed to investigate the safety and preliminary efficacy of Kartigen

Indexed as

cartilage defectchondrocyte precursorsKartigen®kneestem cell therapy

Identifiers

PMID34577930
PMCPMC8466236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.